HOME >> BIOLOGY >> NEWS
Genomic analysis uncovers new targets for HIV vaccine

DURHAM, N.C. -- An international team of researchers has identified three gene variants in the DNA of 486 people infected with HIV that appear to have helped some of the patients fight off the virus and delay the onset of full-blown AIDS.

The researchers expect the new findings to aid the search for an HIV vaccine that would work by boosting the protective effects of one or more of these genes, and help the bodys own immune system overcome an infection. One of the genes looks particularly attractive as a vaccine target.

The study, published early online by the journal Science July 19, was directed by David Goldstein at Duke University and is the first large cooperative study with major findings arising from the Center for HIV/AIDS Vaccine Immunology, (CHAVI) a seven-year project funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, in 2005, led by Dukes Barton Haynes, M.D.

It took the international genetics team, called EuroCHAVI, pooling their cohorts of carefully selected patients and using the latest in genome-wide screening technology, 18 months to discover the three genes, that together greatly increase our knowledge of why patients differ in how well they can control the virus that causes AIDS.

These findings represent only the first of what investigators said will be a series of future genome-wide studies to pinpoint additional targets for HIV vaccines. In the new analysis, patients with specific gene variants in key immune system cells appear to be much better at controlling the proliferation of the virus after infection. These gene variants are known as polymorphisms.

These results not only approximately double our understanding of the factors that influence variation amongst individuals in how they control HIV-1, but also point torward new mechanisms of control, said David Goldstein, Ph.D., director of the Center for Population Genomics and Pha
'"/>

Contact: Richard Merritt
Merri006@mc.duke.edu
919-660-1309
Duke University Medical Center
19-Jul-2007


Page: 1 2 3

Related biology news :

1. Genomics study provides insight into the evolution of unique human traits
2. Psychiatric Genomics Center established at Cold Spring Harbor Laboratory
3. Genomic signatures identify targeted therapies for lung cancer
4. NYUs Center for Comparative Functional Genomics part of $57 million MOD-ENCODE consortium
5. Genomic test could help detect radioactivity exposure from terrorist attacks
6. Elsevier launches new journal, Marine Genomics
7. Genomics throws species definition in question for microbes
8. Genomic variation easier to identify with UCSD/Brown software
9. Springer adds Genomic Medicine to biomedical publishing portfolio
10. Genomic firestorms underlie aggressive breast cancer progression
11. Genomic comparison of lactic acid bacteria published

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Genomic analysis uncovers new targets for HIV vaccine

(Date:5/24/2013)... years, microRNAs (miRNAs) and other non-coding RNAs are ... specific proteins. In recent years they have emerged ... to establish tissue origin for cancers of unknown ... screen for disease, but clinically tractable, diagnostic methods ... not currently available. In this issue of the ...
(Date:5/23/2013)... , Automated conserved noncoding sequence (CNS) discovery ... grasses , Within the genome of each species, ... little change in position and sequence over millions of ... of these evolutionarily stable sequences, so-called conserved noncoding sequences ... genes or the condensation of chromosomes, but the function ...
(Date:5/23/2013)... Rollins School of Public Health at Emory University, ... Technology, have received a $4 million grant over ... Emory University (Health and Exposome Research Center: Understanding ... center grant awarded in the United States. ... National Institute of Environmental Health Sciences (NIEHS) of ...
Breaking Biology News(10 mins):Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3
(Date:5/23/2013)... May 23, 2013 PuraMed BioScience ® ... marketer of over-the-counter (OTC) medicinal and healthcare products, ... on the company based on low market capitalization ... Non-Prescription, All Natural Product to Treat Migraine Headaches ... #1 Prescription Competitor , Currently Available Nationwide ...
(Date:5/23/2013)... Calif. , May 23, 2013  Saddleback Memorial ... recently became the first hospital on the West ... technology. This new surgical option provides women with a ... Marc Winter , M.D., a ... and surgeon and medical director of minimally invasive surgery ...
(Date:5/23/2013)... Md. , May 23, 2013 Northwest ... biotechnology company developing DCVax ® personalized immune therapies ... use its exhibit at this year,s American Society Of ... to highlight its leadership role in immune therapy.  ... The ASCO annual meeting is the pre-eminent conference focused ...
(Date:5/23/2013)... May 23, 2013 Pusan National University ... private biotherapeutics and contract research company focused on ... cancer, announced today a publication reporting the induction ... the oncolytic and immunotherapeutic vaccinia JX-594 (pexastimogene devacirepvec; ... published in the May 15 th , 2013 ...
Breaking Biology Technology:PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3
Cached News: